BR112015021399A2 - anticórpos monoclonais contra antitrombina beta complexada com heparina - Google Patents
anticórpos monoclonais contra antitrombina beta complexada com heparinaInfo
- Publication number
- BR112015021399A2 BR112015021399A2 BR112015021399A BR112015021399A BR112015021399A2 BR 112015021399 A2 BR112015021399 A2 BR 112015021399A2 BR 112015021399 A BR112015021399 A BR 112015021399A BR 112015021399 A BR112015021399 A BR 112015021399A BR 112015021399 A2 BR112015021399 A2 BR 112015021399A2
- Authority
- BR
- Brazil
- Prior art keywords
- heparin
- complexed
- monoclonal antibodies
- antithrombin
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
resumo anticórpos monoclonais contra antitrombina beta complexada com heparina este documento de patente refere-se a anticorpos, fragmentos de anticorpos de ligação ao antigênio (fab), e outros suportes proteicos, dirigido contra ß antitrombina humana complexada com heparina e/ou a estrutura do tipo heparina (atßh). estas proteínas de ligação atßh pode bloquear a atividade anticoagulante de atß para induzir a coagulação. as utilizações terapêuticas destes anticorpos e ligantes são aqui descritos como são os métodos de filtração e pesquisa de anticorpos específicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361784590P | 2013-03-14 | 2013-03-14 | |
PCT/US2014/029541 WO2014153195A1 (en) | 2013-03-14 | 2014-03-14 | Monoclonal antibodies against antithrombin beta complexed with heparin |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015021399A2 true BR112015021399A2 (pt) | 2017-07-18 |
Family
ID=50680168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015021399A BR112015021399A2 (pt) | 2013-03-14 | 2014-03-14 | anticórpos monoclonais contra antitrombina beta complexada com heparina |
Country Status (18)
Country | Link |
---|---|
US (4) | US20140271660A1 (pt) |
EP (1) | EP2970500A1 (pt) |
JP (1) | JP2016519081A (pt) |
KR (1) | KR20150127202A (pt) |
CN (1) | CN105229033B (pt) |
AR (1) | AR095499A1 (pt) |
AU (1) | AU2014236198A1 (pt) |
BR (1) | BR112015021399A2 (pt) |
CA (1) | CA2916421A1 (pt) |
HK (1) | HK1215261A1 (pt) |
MX (1) | MX2015012441A (pt) |
PE (1) | PE20160533A1 (pt) |
RU (1) | RU2015143696A (pt) |
SG (1) | SG11201506886TA (pt) |
TW (1) | TW201529602A (pt) |
UY (1) | UY35457A (pt) |
WO (1) | WO2014153195A1 (pt) |
ZA (1) | ZA201507628B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2916421A1 (en) | 2013-03-14 | 2014-09-25 | Bayer Healthcare Llc | Monoclonal antibodies against antithrombin beta complexed with heparin |
US10356677B2 (en) * | 2014-05-19 | 2019-07-16 | Nokia Solutions And Networks Oy | Re-establishment procedure in dual connectivity networks |
DK3313879T3 (da) | 2015-06-24 | 2022-03-14 | Hoffmann La Roche | Anti-transferrinreceptor-antistoffer med tilpasset affinitet |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
CN114014936A (zh) | 2015-10-02 | 2022-02-08 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
EP3430059A1 (en) * | 2016-03-18 | 2019-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-antithrombin single-domain antibodies and polypeptides comprising thereof |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5578253A (en) | 1978-12-11 | 1980-06-12 | Teikoku Hormone Mfg Co Ltd | Immune measurement of hito antithrombin 3 |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
BE896543A (fr) | 1983-04-22 | 1983-08-16 | Wallone Region | Ensembles d'anticorps monoclonaux deriges contre les proteines humaines impliquees dans la coagulation et la fibrinolyse du sang |
JPH0644876B2 (ja) | 1985-12-13 | 1994-06-15 | 株式会社ヤトロン | 抗トロンビン・アンチトロンビン3複合体モノクローナル抗体、及びその製造方法、並びにそれを用いるトロンビン・アンチトロンビン3複合体の免疫定量法、及びそれを用いるトロンビン・アンチトロンビン3複合体の精製方法 |
JPH0266458A (ja) | 1988-09-01 | 1990-03-06 | Takara Shuzo Co Ltd | ビトロネクチン及びビトロネクチン‐トロンビン‐アンチトロンビン3複合体の測定方法 |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
AU628960B2 (en) | 1989-04-07 | 1992-09-24 | Teijin Limited | Method of immunologically assaying human thrombin- antithrombin III complex, assay reagent and kit therefor |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
JPH0694713A (ja) | 1991-07-31 | 1994-04-08 | Masashi Funayama | アンチトロンビンiii活性の測定方法とそれを用いたアンチトロンビンiii活性の測定キット |
JPH07238099A (ja) | 1994-02-25 | 1995-09-12 | Dai Ichi Pure Chem Co Ltd | モノクローナル抗体及びこれを用いる免疫学的測定法 |
FR2718849B1 (fr) | 1994-04-14 | 1996-06-14 | Pasteur Sanofi Diagnostics | Procédé d'immunodosage de l'antithrombine III activée par un glycosaminoglycane, anticorps monoclonaux correspondants et leur procédé d'obtention. |
US5753445A (en) | 1994-04-26 | 1998-05-19 | The Mount Sinai Medical Center Of The City University Of New York | Test for the detection of anti-heparin antibodies |
JP3841364B2 (ja) | 1994-10-18 | 2006-11-01 | 株式会社三菱化学ヤトロン | 抗ヒトビトロネクチン・トロンビン・アンチトロンビンiii 複合体モノクローナル抗体、ハイブリドーマ及び免疫学的測定方法 |
ATE403001T1 (de) | 1996-05-22 | 2008-08-15 | Viventia Biotech Inc | Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs |
WO1997045538A1 (en) | 1996-05-31 | 1997-12-04 | Medigene Ag | Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces |
DE60037513T2 (de) | 1999-05-13 | 2009-02-05 | GTC Biotherapeutics, Inc., Framingham | Transgene hergestellte antithrombin iii und deren mutanten |
JP2001321167A (ja) | 2000-05-10 | 2001-11-20 | Cosmo Research Inst | モノクローナル抗体 |
PT2275449T (pt) | 2000-06-16 | 2016-12-27 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
JP2002316999A (ja) | 2001-04-17 | 2002-10-31 | Dai Ichi Pure Chem Co Ltd | モノクローナル抗体 |
US20090226429A1 (en) | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
AU2003234706A1 (en) | 2002-04-15 | 2003-11-03 | Human Genome Sciences, Inc. | Antibodies that specifically bind to tl5 |
ATE522601T1 (de) | 2002-05-31 | 2011-09-15 | Univ Utah Res Found | Varianten von antithrombin iii |
EP1382615A1 (en) | 2002-07-15 | 2004-01-21 | Xerion Pharmaceuticals AG | MCAM inhibitors |
AU2003289716A1 (en) | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
RU2262109C2 (ru) | 2002-12-30 | 2005-10-10 | Институт биохимической физики им. Н.М. Эмануэля Российской академии наук | Способ определения концентрации антитромбина iii в плазме крови |
EP2184298A1 (en) | 2003-03-14 | 2010-05-12 | Wyeth a Corporation of the State of Delaware | Antibodies against human IL-21 receptor and uses therefor |
EP1633316A4 (en) | 2003-05-06 | 2008-04-02 | Human Genome Sciences Inc | ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS |
GB2404981A (en) | 2003-08-15 | 2005-02-16 | Univ Geneve | Diagnostic method for stroke |
AU2004290017B2 (en) | 2003-11-07 | 2012-05-03 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
US7271245B2 (en) | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | hK1結合タンパク質 |
JP4829609B2 (ja) | 2004-12-22 | 2011-12-07 | 独立行政法人科学技術振興機構 | ヒト抗体酵素およびその生産方法 |
EP1848672A4 (en) | 2005-02-01 | 2009-11-04 | Morphosys Ag | BANKS AND METHODS FOR ISOLATING ANTIBODIES |
ATE539764T1 (de) | 2007-07-20 | 2012-01-15 | Univ Paris Sud Xi | Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungen |
WO2009021754A2 (en) | 2007-08-15 | 2009-02-19 | Bayer Schering Pharma Aktiengesellschaft | Monospecific and multispecific antibodies and method of use |
KR101529743B1 (ko) | 2007-11-29 | 2015-06-17 | 그리폴스 테라퓨틱스 인코포레이티드 | 재조합적으로 변형된 플라스민 |
ES2346618B1 (es) | 2008-08-14 | 2011-08-03 | Universidad De Murcia | Anticuerpo monoclonal anti antitrombina citrulinada humana y sus usos. |
NO330078B1 (no) | 2008-09-22 | 2011-02-14 | Optipro As | Fremgangsmåte og apparat for å overvåke slitasje i sikteduker |
WO2010047830A2 (en) | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | Agents for hcv treatment |
AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
EP3401333B1 (en) | 2010-09-09 | 2021-05-19 | Purdue Research Foundation | Anti-human folate receptor beta antibodies and methods of use |
US20140356377A1 (en) | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
EP2776603B1 (en) | 2011-11-11 | 2019-03-06 | SiO2 Medical Products, Inc. | PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS |
CA2916421A1 (en) * | 2013-03-14 | 2014-09-25 | Bayer Healthcare Llc | Monoclonal antibodies against antithrombin beta complexed with heparin |
JP6094713B1 (ja) | 2016-06-30 | 2017-03-15 | 富士ゼロックス株式会社 | 定着部材、定着装置、及び画像形成装置 |
-
2014
- 2014-03-14 CA CA2916421A patent/CA2916421A1/en not_active Abandoned
- 2014-03-14 TW TW103109449A patent/TW201529602A/zh unknown
- 2014-03-14 AU AU2014236198A patent/AU2014236198A1/en not_active Abandoned
- 2014-03-14 MX MX2015012441A patent/MX2015012441A/es unknown
- 2014-03-14 CN CN201480028085.2A patent/CN105229033B/zh not_active Expired - Fee Related
- 2014-03-14 US US14/214,267 patent/US20140271660A1/en not_active Abandoned
- 2014-03-14 KR KR1020157028131A patent/KR20150127202A/ko not_active Application Discontinuation
- 2014-03-14 WO PCT/US2014/029541 patent/WO2014153195A1/en active Application Filing
- 2014-03-14 UY UY0001035457A patent/UY35457A/es not_active Application Discontinuation
- 2014-03-14 EP EP14722465.3A patent/EP2970500A1/en not_active Withdrawn
- 2014-03-14 BR BR112015021399A patent/BR112015021399A2/pt not_active IP Right Cessation
- 2014-03-14 PE PE2015001972A patent/PE20160533A1/es not_active Application Discontinuation
- 2014-03-14 US US14/214,382 patent/US9593166B2/en not_active Expired - Fee Related
- 2014-03-14 US US14/770,222 patent/US9908942B2/en not_active Expired - Fee Related
- 2014-03-14 SG SG11201506886TA patent/SG11201506886TA/en unknown
- 2014-03-14 RU RU2015143696A patent/RU2015143696A/ru not_active Application Discontinuation
- 2014-03-14 JP JP2016503128A patent/JP2016519081A/ja active Pending
- 2014-03-14 AR ARP140101104A patent/AR095499A1/es unknown
-
2015
- 2015-10-13 ZA ZA2015/07628A patent/ZA201507628B/en unknown
-
2016
- 2016-03-17 HK HK16103100.3A patent/HK1215261A1/zh unknown
-
2018
- 2018-02-28 US US15/908,705 patent/US10144784B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2014153195A1 (en) | 2014-09-25 |
US9908942B2 (en) | 2018-03-06 |
US20160024222A1 (en) | 2016-01-28 |
TW201529602A (zh) | 2015-08-01 |
KR20150127202A (ko) | 2015-11-16 |
US10144784B2 (en) | 2018-12-04 |
AU2014236198A1 (en) | 2015-10-15 |
US20180244799A1 (en) | 2018-08-30 |
ZA201507628B (en) | 2017-11-29 |
JP2016519081A (ja) | 2016-06-30 |
MX2015012441A (es) | 2016-08-08 |
US20140271661A1 (en) | 2014-09-18 |
SG11201506886TA (en) | 2015-09-29 |
AR095499A1 (es) | 2015-10-21 |
UY35457A (es) | 2014-10-31 |
RU2015143696A (ru) | 2017-04-19 |
US20140271660A1 (en) | 2014-09-18 |
CN105229033A (zh) | 2016-01-06 |
CA2916421A1 (en) | 2014-09-25 |
PE20160533A1 (es) | 2016-06-09 |
EP2970500A1 (en) | 2016-01-20 |
CN105229033B (zh) | 2019-04-23 |
US9593166B2 (en) | 2017-03-14 |
HK1215261A1 (zh) | 2016-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015021399A2 (pt) | anticórpos monoclonais contra antitrombina beta complexada com heparina | |
CL2019003728A1 (es) | Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf. (divisional solicitud 201701000) | |
BR112018072485A2 (pt) | proteínas de ligação biespecíficas e usos das mesmas | |
BR112019005292A2 (pt) | anticorpos para siglec-15 e métodos de uso dos mesmos. | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
BR112018006531A2 (pt) | proteína isolada de ligação ao antígeno (abp), polinucleotídeo isolado, vetor, célula hospedeira, método para produzir uma proteína isolada de ligação ao antígeno (abp), composição farmacêutica, método para tratar ou prevenir uma doença ou condição num sujeito em necessidade deste, método para modular uma resposta imune num indivíduo em necessidade deste e kit | |
BR112017025529A2 (pt) | agentes de ligação ao tigit e usos destes | |
BR112015029395A2 (pt) | Anticorpos anti-b7-h5 e seus usos | |
EA201692539A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
BR112013027021A2 (pt) | anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos | |
CO7160115A2 (es) | Proteinas de unión a antigeno que se unen a pd-l1 | |
BR112017003108A8 (pt) | Anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
EA201591762A1 (ru) | Человеческие антитела к grem1 | |
UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
BR112018011336A2 (pt) | anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer | |
EA201290570A1 (ru) | Конструкты, связывающиеся с ron, и способы их использования | |
BR112012009854A2 (pt) | proteína de ligação de antígeno il-23 humana | |
UY33319A (es) | PROTEÍNAS QUE SE UNEN AL TNF-a | |
BRPI0708101B8 (pt) | anticorpo, ou seu fragmento de ligação a antígeno, que especificamente se liga a il-22, composição farmacêutica, ácido nucléico isolado, vetor de expressão, célula hospedeira, método de produção do mesmo e kit diagnóstico | |
EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
EA201790438A1 (ru) | Антигенсвязывающие белки, которые связываются с cxcr5 | |
EA201690503A1 (ru) | Антитела | |
BR112017002703A2 (pt) | anticorpos específicos de mmp9. | |
BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law | ||
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |